Tonix Pharmaceuticals
Clinical-stage biotechnology company developing small molecules and biologics across central nervous system, immunology/immuno-oncology, and infectious disease/biodefense. Maintains an in-house research facility with BSL-2/BSL-3 capability, advances programs from preclinical stages through late-phase clinical trials, and collaborates with academic, government and industry partners.
Industries
Nr. of Employees
medium (51-250)
Tonix Pharmaceuticals
Berkeley Heights, New Jersey, United States
Patents
Products
Sublingual cyclobenzaprine formulation (sublingual CBP)
Transmucosal (sublingual) formulation of cyclobenzaprine developed for treatment of fibromyalgia and trauma-related indications; advanced through Phase 3 clinical studies with reported pharmacokinetic characterization and efficacy analyses.
Live replicating orthopoxvirus vaccine platform
Single-dose live attenuated orthopoxvirus vaccine platform designed to express exogenous antigens to elicit predominantly cellular immune responses for prevention of orthopoxvirus and other emerging viral infections.
Monoclonal antibody candidates (long-acting and Fc-modified)
Programs include long-acting bactericidal human monoclonal antibodies for prevention of infectious diseases and Fc-modified antibodies evaluated for immunomodulation in transplantation and oncology.
TNX-4700
A human anti-BTLA monoclonal antibody (mAb) being developed for immuno-oncology indications.
TNX-102 SL
A patented sublingual tablet formulation of cyclobenzaprine hydrochloride designed to provide rapid transmucosal absorption and reduced production of norcyclobenzaprine.
Zembrace SymTouch
Zembrace SymTouch (sumatriptan succinate) injection is a prefilled, ready-to-use, single-dose disposable auto-injector indicated for the acute treatment of migraine with or without aura in adults.
Sublingual cyclobenzaprine formulation (sublingual CBP)
Transmucosal (sublingual) formulation of cyclobenzaprine developed for treatment of fibromyalgia and trauma-related indications; advanced through Phase 3 clinical studies with reported pharmacokinetic characterization and efficacy analyses.
Live replicating orthopoxvirus vaccine platform
Single-dose live attenuated orthopoxvirus vaccine platform designed to express exogenous antigens to elicit predominantly cellular immune responses for prevention of orthopoxvirus and other emerging viral infections.
Monoclonal antibody candidates (long-acting and Fc-modified)
Programs include long-acting bactericidal human monoclonal antibodies for prevention of infectious diseases and Fc-modified antibodies evaluated for immunomodulation in transplantation and oncology.
TNX-4700
A human anti-BTLA monoclonal antibody (mAb) being developed for immuno-oncology indications.
TNX-102 SL
A patented sublingual tablet formulation of cyclobenzaprine hydrochloride designed to provide rapid transmucosal absorption and reduced production of norcyclobenzaprine.
Zembrace SymTouch
Zembrace SymTouch (sumatriptan succinate) injection is a prefilled, ready-to-use, single-dose disposable auto-injector indicated for the acute treatment of migraine with or without aura in adults.
Expertise Areas
- Clinical trial management
- Vaccine platform development (live viral vectors)
- Monoclonal antibody therapeutics
- Central nervous system therapeutics
Key Technologies
- Synthetic biology for viral vector design
- Live attenuated orthopoxvirus vectors
- Monoclonal antibody discovery and Fc engineering
- Transmucosal (sublingual) drug-delivery platforms
News & Updates
Positive Phase 3 efficacy results and multiple scientific presentations reporting clinically meaningful improvements, pooled analyses, and pharmacokinetic characterizations for a sublingual cyclobenzaprine formulation in fibromyalgia.
Pooled analysis results including number-needed-to-treat and number-needed-to-harm metrics and other pooled outcome measures presented at scientific meetings.
Preclinical data reported that a single dose of a recombinant orthopoxvirus-based vaccine protected macaques from lethal monkeypox challenge in published and presented studies.
Early-phase clinical data for a long-acting monoclonal antibody were presented and plans for an adaptive Phase 2 field study were described at a ticks and tickborne diseases symposium.
Steady-state PK properties of a sublingual formulation were presented with comparisons to simulated oral immediate-release pharmacokinetics.
Positive Phase 3 efficacy results and multiple scientific presentations reporting clinically meaningful improvements, pooled analyses, and pharmacokinetic characterizations for a sublingual cyclobenzaprine formulation in fibromyalgia.
Pooled analysis results including number-needed-to-treat and number-needed-to-harm metrics and other pooled outcome measures presented at scientific meetings.
Preclinical data reported that a single dose of a recombinant orthopoxvirus-based vaccine protected macaques from lethal monkeypox challenge in published and presented studies.
Early-phase clinical data for a long-acting monoclonal antibody were presented and plans for an adaptive Phase 2 field study were described at a ticks and tickborne diseases symposium.
Steady-state PK properties of a sublingual formulation were presented with comparisons to simulated oral immediate-release pharmacokinetics.